Pre-exposure prophylaxis for HIV prevention: how to predict success

Affiliations

¹ UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: akashuba@unc.edu.
² Center for Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
³ UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Angela Dm Kashuba et al. Lancet. 2012.

. 2012 Jun 30;379(9835):2409-2411.

doi: 10.1016/S0140-6736(11)61852-7. Epub 2011 Dec 6.

¹ UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: akashuba@unc.edu.
² Center for Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
³ UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

No abstract available

Conflict of interest statement

JBD and MSC declare that they have no conflicts of interest.

Predicting effect of pre-exposure prophylaxis on HIV epidemics.
Supervie V, Blower S. Supervie V, et al. Lancet. 2012 Jun 30;379(9835):2423. doi: 10.1016/S0140-6736(12)61057-5. Lancet. 2012. PMID: 22748579 No abstract available.

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. - PMC - PubMed
1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74. - PMC - PubMed
1. [accessed Nov 28, 2011];VOICE (MTN-003) Microbicide Trials Network. http://www.mtnstopshiv.org/news/studies/mtn003.
1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. - PMC - PubMed
1. Thigpen M, Kebaabetswe P, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. 6th IAS Conference; July 17–20, 2011; Rome, Italy. [accessed Nov 28, 2011]. WELBC01 oral abstract. http://pag.ias2011.org/abstracts.aspx?aid=4631.